Sander van Deventer

Bio

Dr van Deventer has extensive experience in translational research with particular emphasis on drug development, and significant regulatory experience with the European Agency for the Evaluation of Medicinal Products (EMEA) and Food and Drug Administration (FDA.) He is both partner with Forbion Capital Partners, and professor of Experimental Medicine at the University of Amsterdam Medical School (AMC). Dr van Deventer was part of the original ABN AMRO Capital Life Sciences (AAC LS) team, before it became the independent body Forbion. He joined as venture partner at AAC LS in 2004. In 1995, Dr van Deventer became director of the laboratory for Experimental Internal Medicine at the Academic Medical Center in Amsterdam, where he worked on therapeutic signal transduction inhibition, gene therapy, and (genetically engineered) probiotics. His scientific involvement included the organization of the genomics and proteomics initiative at the University of Amsterdam. In addition, Dr van Deventer was Chairman of the Anton Meelmeijer Center for Genomics and Proteomics. From 2001 until 2004, he was chairman of the Department of Gastroenterology and Hepatology at the Academic Medical Center in Amsterdam. Dr van Deventer has significant experience in the medical and life sciences field. As such, he has been a consultant to all major pharma and to a significant number of large biotech companies. He is co-founder of the gene therapy company Amsterdam Molecular Therapeutics, and currently holds a part-time position on the company’s board as Chief Scientific Officer. Dr van Deventer holds two other board seats, at Argos Therapeutics in Durham, NC, US, and at Borean Pharma, Arhus, Denmark. Dr van Deventer was trained and board certified in internal medicine and gastroenterology, and received his medical degree and doctor of philosophy from the University of Amsterdam. His thesis was based on the biological activities of bacterial lipopolysaccharides in humans.